PEAK6’s Sutro Biopharma STRO Stock Holding History

PEAK6’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,131	Closed	-$15.2K	–	3453
2025 Q2	$15.2K	Hold	2,131	–	–	﹤0.01%	2765
2025 Q1	$13.9K	Hold	2,131	–	–	﹤0.01%	2776
2024 Q4	$39.2K	Buy	+2,131	New	+$65.1K	﹤0.01%	2858

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

PEAK6's STRO Position: Q3 2025 in Review

PEAK6 sold out of Sutro Biopharma (STRO) in Q3 2025, closing a stake of 2,131 shares — an estimated $15.2K sold.

PEAK6 first reported a position in STRO in Q4 2024 and held it in 3 quarters. The position peaked at $39.2K in Q4 2024. 87 funds tracked by Wall St. Rank hold STRO as of Q3 2025.

PEAK6 reported no remaining Sutro Biopharma position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 2,131 Sutro Biopharma shares in Q3 2025, an estimated $15.2K.
PEAK6 first reported a position in Sutro Biopharma in Q4 2024 and held it in 3 quarters.
PEAK6's Sutro Biopharma position peaked at $39.2K in Q4 2024.
87 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.